Gilead Sciences Sees Unusually High Options Volume (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) saw some unusual options trading activity on Tuesday. Investors purchased 16,499 put options on the stock. This is an increase of 107% compared to the typical volume of 7,952 put options.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts continue to favor Gilead, with multiple firms raising price targets to between $175 and $200. Morgan Stanley upgraded or reiterated a Buy-equivalent view, while broader coverage remains predominantly bullish. Gilead Sciences Stock: Analyst Estimates & Ratings
• Positive Sentiment: Gilead will present data from more than 50 studies at HIV Glasgow 2026, including late-breaking clinical results, real-world evidence and updates on strategic collaborations. Positive results could reinforce confidence in the company’s leading HIV business and development pipeline. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
• Positive Sentiment: BioNTech disclosed progress on a planned Phase 3 study of its pumitamig candidate combined with Gilead’s TROP2-directed cancer therapy Trodelvy in triple-negative breast cancer. The collaboration could support the long-term value of Gilead’s oncology pipeline, subject to regulatory approval. BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
• Neutral Sentiment: Gilead recently reported quarterly earnings above analyst expectations, with revenue also exceeding forecasts and increasing year over year. However, the company’s revenue guidance improvement was accompanied by a weaker EPS outlook, creating a mixed near-term earnings signal. Gilead Sciences Q3 2026 Earnings Analysis
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions worth about $5.3 million. Both sales were conducted under a pre-arranged Rule 10b5-1 trading plan, reducing the signal’s significance, but the transactions may still weigh modestly on investor sentiment. Gilead Sciences Stock: Insider Daniel Patrick O’Day Sells Shares

Gilead Sciences Stock Down 0.8%

Shares of GILD traded down $1.28 during midday trading on Tuesday, reaching $169.05. 1,750,105 shares of the company were exchanged, compared to its average volume of 6,802,594. The stock has a 50-day moving average price of $151.36 and a 200-day moving average price of $140.03. The company has a market cap of $209.61 billion, a price-to-earnings ratio of -53.50 and a beta of 0.31. Gilead Sciences has a 1-year low of $116.88 and a 1-year high of $175.65. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same quarter in the prior year, the business earned $2.47 earnings per share. The company’s revenue was up 6.8% compared to the same quarter last year. Research analysts expect that Gilead Sciences will post -1.03 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 1.9%. Gilead Sciences’s payout ratio is -103.80%.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the transaction, the insider directly owned 113,684 shares of the company’s stock, valued at approximately $17,759,714.48. This trade represents a 2.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer owned 161,096 shares in the company, valued at $25,166,417.12. The trade was a 1.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 126,881 shares of company stock worth $19,252,455. 0.30% of the stock is currently owned by company insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently made changes to their positions in GILD. PFS Partners LLC lifted its holdings in Gilead Sciences by 101.1% in the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 96 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in Gilead Sciences in the 2nd quarter valued at about $25,000. Laurel Wealth Advisors LLC purchased a new position in Gilead Sciences in the 3rd quarter valued at about $29,000. Kimelman & Baird LLC acquired a new stake in shares of Gilead Sciences during the second quarter valued at about $25,000. Finally, Toth Financial Advisory Corp grew its stake in shares of Gilead Sciences by 85.5% during the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GILD. Cantor Fitzgerald lifted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday. BMO Capital Markets restated an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a report on Friday. HSBC raised their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $185.00 price target on shares of Gilead Sciences in a research report on Friday, October 23rd. Finally, Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $169.74.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.